A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)

NCT ID: NCT00751218

Last Updated: 2024-08-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 174 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-05-06
• Study Completion Date: 2005-05-24

Brief Summary

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.

Conditions

Urticaria

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Arm 1

desloratadine

Group Type: ACTIVE_COMPARATOR

desloratadine

Intervention Type: DRUG

desloratadine, 5mg oral tablets, once daily for 28 days

Arm 2

Placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

placebo, once daily for 28 days

Arm 3

cetirizine

Group Type: ACTIVE_COMPARATOR

cetirizine

Intervention Type: DRUG

cetirizine, 10 mg capsules once daily for 28 days

Interventions

desloratadine

desloratadine, 5mg oral tablets, once daily for 28 days

Intervention Type: DRUG

placebo

placebo, once daily for 28 days

Intervention Type: DRUG

cetirizine

cetirizine, 10 mg capsules once daily for 28 days

Intervention Type: DRUG

Other Intervention Names

SCH 034117

Eligibility Criteria

Inclusion Criteria

• Have demonstrated their willingness to participate in the study and comply with its procedures by signing a written informed consent. For pediatric patients, the parent or legal guardian was to have signed a written informed consent.
• Be between 12 and 70 years of age, of either sex and any race.
• Had signs and symptoms of CIU for at least 6 weeks prior to the Screening Visit.
• Have been experiencing a current flare of their CIU of at least 3 weeks prior to the Baseline Visit. Hives were to have been present for at least 3 days per week during the current flare prior to the Baseline Visit.
• Have an overall condition of CIU that was at least of "moderate" severity (minimum score of 2) at both Screening and Baseline Visits.
• Have at least a moderately severe pruritus score (minimum score of 2) and hives (minimum score of 1) present at Screening.
• Have, at Baseline, a total pruritus score of >= 14 for the sum of AM and PM (reflective) diary scores for the 3 days prior to Baseline and the AM diary score on Day 1.
• Understand and be able to adhere to the dosing and visit schedules, and agree to assess and record their symptom severity scores, medication times, concomitant medications, and adverse events accurately and consistently in a daily diary.
• Be in general good health and free of any clinically significant disease (other than CIU) that would have interfered with study evaluations.
• If female and of childbearing potential, have had a negative urine (hCG) pregnancy test at the time of Baseline (Visit 2).
• Female subjects of childbearing potential were to be counseled in the appropriate use of birth control while in the study. They were to be using a medically accepted method of birth control

Exclusion Criteria

• Had asthma requiring chronic use of inhaled or systemic corticosteroids.
• Had been unresponsive to antihistamine treatment in the past.
• Had a history of allergies to more than two classes of medication or who were allergic to or unable to tolerate antihistamines.
• Had used any investigational drug in the last 30 days prior to Baseline.
• Had food or drug allergies manifested as skin reactions. Subjects with urticaria that was primarily due to physical urticaria or other known etiology.
• If female, were pregnant or nursing.
• Had a history of hypersensitivity to the study drug or its excipients.
• Were family members of the investigational study staff involved with this study.
• Had previously been randomized into the study.
• Had current evidence of clinically significant hematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric, autoimmune disease, or other disease that precluded the subject's participation in the study. Particular attention was to be given to subjects with conditions that would interfere with the absorption, distribution, metabolism, or excretion of the study medication or with the subject's ability to reliably complete the diary card.
• Were morbidly obese (BMI >= 35, as described in Appendix 6 of the protocol)
• Had a compromised ability to provide informed consent.
• Had a history of non-compliance with medications or treatment protocols.

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Organon and Co

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Other Identifiers

P03735

Identifier Type: -

Identifier Source: org_study_id